Lagevrio® (molnupiravir) is a Prescription Medicine and is available as 200 mg capsules.
Please review the Lagevrio Data Sheet before prescribing. The Data Sheet is available at www.medsafe.govt.nz.
CONTRAINDICATIONS: Hypersensitivity to the active substance or to any of the excipients.
PRECAUTIONS: Use in pregnancy is not recommended; consider the need for a pregnancy test before initiating treatment in women of childbearing potential who are sexually active. It is recommended that sexually active women of childbearing potential use contraception during and for 4 days after the last dose, and that men who are sexually active with a partner of childbearing potential use an adequate form of contraception during and for 3 months after treatment. Breastfeeding is not recommended during treatment and for 4 days after the last dose. Safety and efficacy of Lagevrio have not been established in patients ≤ 18 years, therefore use in paediatric patients is not recommended. Hypersensitivity reactions have been reported; if signs and symptoms of a clinically significant hypersensitivity reaction occur, immediately discontinue Lagevrio and initiate appropriate medications and/or supportive care.
INTERACTIONS: No drug interactions have been identified based on the limited available data. Potential for interaction with concomitant medications is considered unlikely.
ADVERSE EVENTS: Common: diarrhoea, nausea, dizziness. The following have been reported in post-marketing experience:hypersensitivity, angioedema, erythema, rash, urticaria.
DOSAGE AND ADMINISTRATION: Adults: 800 mg (four 200 mg capsules) taken orally every 12 hours for 5 days, with or without food. Safety and efficacy when administered for periods longer than 5 days have not been established. Lagevrio should be administered as soon as possible after a diagnosis of COVID-19 has been made and within 5 days of symptom onset. Based on Data Sheet dated 14 April 2022.
Merck Sharp & Dohme (New Zealand) Limited. Level 3, 123 Carlton Gore Road, Newmarket, Auckland.
Copyright © 2022 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved.
NZ-LAG-00012. First issued May 2022. TAPS DA2208KN.